FDA approves latest Humira near-copy, as dozens of biosimila...

The FDA has approved Pfizer’s biosimilar of AbbVie’s blockbuster Humira (adalimumab), meaning that there are now five of these cheaper near-copies teed up to compete when the originator’s p

Vyndaqel romps away in US, spurring earnings hike from Pfize...

Which big pharma firms are best at digital?

New research by The Worldcom Public Relations Group has ranked pharmaceutical companies according to their usage of digital channels – with Bayer, Pfizer and Boehringer Ingelheim coming out

Pfizer’s Xeljanz follow-up abrocitinib gathers momentum

ImaginAb joins with AZ, Pfizer and Takeda to develop tumour ...

LA-based biotech ImaginAb has signed a multi-party agreement with pharma giants AstraZeneca, Pfizer, and Takeda, for technology that allows scientists to see inside tumours, and monitor whe

Pfizer inks deal with Ionis and Akcea for potential blockbus...

Pfizer has signed a deal with Ionis’ affiliate Akcea Therapeutics, to develop a potential blockbuster antisense therapy to treat patients with certain cardiovascular and metabolic diseases